IDEXX Laboratories, Inc.
IDXX
$554.99
+1.82%
IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics, providing in-office test kits, benchtop analyzers, reference laboratory services, and practice management software for veterinarians and livestock producers. The company holds a dominant market position in the companion animal diagnostics space, with a comprehensive product portfolio and a strong brand trusted by veterinary practices worldwide. Currently, the stock is under scrutiny as it navigates a post-pandemic normalization in pet healthcare spending, with recent quarterly results showing robust growth and raised guidance, yet the share price has declined significantly over the past year, reflecting investor concerns about valuation and growth sustainability.…
IDXX
IDEXX Laboratories, Inc.
$554.99
Related headlines
Investment Opinion: Should I buy IDXX Today?
Rating: Hold. IDEXX is a high-quality company with strong fundamentals, but the current valuation limits upside. The analyst consensus is Buy with an average target of $698.92, implying 25.5% upside, but the stock's premium valuation and recent underperformance warrant caution. The thesis is that IDEXX's growth and margins justify a premium, but not at any price; the stock is fairly valued to slightly overvalued at current levels.
Sign up to view all
IDXX 12-Month Price Forecast
The AI assessment is neutral with medium confidence. IDEXX's fundamentals are strong, with accelerating growth and high margins, but the valuation is rich and the stock has been in a downtrend. The key factor is whether growth can sustain at current levels; if it does, the stock is undervalued, but if not, the premium will compress. The stance would upgrade to bullish if the stock breaks above $600 on strong earnings, or downgrade to bearish if it falls below $520.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $698.92 and implied upside of +25.9% versus the current price.
Average Target
$698.92
0 analysts
Implied Upside
+25.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$470 - $805
Analyst target range
IDEXX has coverage from 13 analysts, with a consensus recommendation of 'Buy' and a mean rating of 2.21 (where 1 is Strong Buy and 5 is Sell). The average price target is $698.92, implying a 25.5% upside from the current price of $556.93. The distribution includes 8 Buy ratings, 4 Hold, and 1 Sell, indicating a generally bullish sentiment but with some caution. The high target of $805 suggests potential for a 44.5% upside, while the low target of $470 implies a 15.6% downside, reflecting a wide range of outcomes. Recent ratings have been stable, with no major upgrades or downgrades in the past six months, but the wide spread between high and low targets indicates uncertainty about the pace of growth recovery and valuation normalization.
Bulls vs Bears: IDXX Investment Factors
IDEXX presents a classic growth-at-a-premium dilemma. The bull case is anchored by accelerating revenue growth (14.3% YoY), raised guidance, and dominant market position with high margins, while the bear case centers on a rich valuation (51.4x trailing PE) and a stock that has underperformed the market by 32.5% over the past year. The most important tension is whether the expected EPS growth of ~54% (implied by the forward PE) materializes; if it does, the stock is undervalued, but if growth decelerates, the premium valuation could compress sharply. Currently, the evidence slightly favors the bulls given the strong fundamentals and analyst consensus, but the risk-reward is balanced, making a 'Hold' appropriate for most investors.
Bullish
- Revenue growth accelerating to 14.3%: Q1 2026 revenue of $1.14 billion grew 14.3% YoY, up from 9.3% in Q1 2025, indicating strong momentum in clinical visits and diagnostic frequency. This acceleration suggests the post-pandemic normalization is resolving favorably.
- Raised guidance signals confidence: Management raised long-term guidance on higher clinical visits and diagnostic frequency, reflecting robust demand in pet healthcare. This positive outlook supports the forward PE of 33.3x, implying expected EPS growth of ~54%.
- Dominant market position with high margins: IDEXX holds a leading share in veterinary diagnostics, with gross margin at 61.8% and operating margin at 31.6% (Q1 2026). These metrics are well above industry averages, underpinning pricing power and operational efficiency.
- Analyst consensus is Buy with 25.5% upside: 13 analysts rate IDXX a Buy (mean 2.21), with an average target of $698.92, implying 25.5% upside from $556.93. The high target of $805 suggests even greater potential if growth sustains.
Bearish
- Premium valuation at 51.4x trailing PE: IDXX trades at 51.4x trailing earnings, a 106% premium to the industry average of 25x. Even the forward PE of 33.3x is elevated, leaving little room for error if growth disappoints.
- Stock down 12% over past year: The share price has fallen 12.0% in the last year and 16.9% YTD, underperforming the S&P 500 by 32.5% relative strength. This persistent downtrend reflects investor skepticism about valuation and growth sustainability.
- High beta amplifies market risk: With a beta of 1.542, IDXX is 54% more volatile than the market. In a rising rate environment or market selloff, the stock could experience outsized declines, as seen in its -31.34% max drawdown.
- PEG ratio of 2.3 suggests overvaluation: The PEG ratio of 2.3 indicates the stock is expensive relative to its growth rate. Even with strong growth, the market is paying a premium that may not be justified if growth decelerates.
IDXX Technical Analysis
IDEXX is currently in a clear downtrend, with the stock price down 12.0% over the past year and 16.9% year-to-date. The current price of $556.93 sits at 72.3% of its 52-week range (between $518.55 low and $769.98 high), indicating it is closer to the lower end of its yearly range, which typically suggests bearish sentiment or a potential value opportunity if fundamentals support a floor. The stock has underperformed the S&P 500 significantly, with relative strength of -32.5% over the past year, highlighting persistent selling pressure.
Beta
1.54
1.54x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$519-$770
Price range past year
Annual Return
-14.2%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | +5.5% |
| 3m | -1.5% | +1.7% |
| 6m | -15.5% | +12.2% |
| 1y | -14.2% | +18.6% |
| ytd | -17.2% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
IDEXX's revenue growth remains solid, with Q1 2026 revenue of $1.14 billion, up 14.3% year-over-year, accelerating from the 9.3% growth seen in Q1 2025. The company has consistently grown revenue over the past eight quarters, from $954 million in Q4 2024 to $1.14 billion in Q1 2026, driven by higher clinical visits and diagnostic frequency, as noted in recent earnings. Product revenue of $666 million and service revenue of $475 million show a balanced mix, with services growing faster, reflecting the strength of the reference lab business.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Given IDEXX's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 51.4x, while the forward PE is 33.3x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests an expected EPS growth of about 54%, which is optimistic but supported by the company's raised guidance. Compared to the industry average PE of 25x (from valuation data), IDEXX trades at a 106% premium, reflecting its market leadership and superior margins, but the premium may be hard to justify if growth decelerates.
PE
51.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.67, which is manageable but not negligible, and a current ratio of 1.17, indicating adequate liquidity. The company's high operating leverage means any revenue shortfall could disproportionately impact earnings, as seen in the 31.3% max drawdown. Additionally, the stock's valuation leaves no margin of safety; a 10% earnings miss could trigger a de-rating, potentially pushing the stock down 20-30% given the high multiple. Free cash flow of $1.08 billion provides a buffer, but it is not sufficient to offset a severe growth slowdown.
FAQ
The key risks are: (1) Valuation risk - the stock trades at a 106% premium to the industry PE, so any growth slowdown could cause a sharp de-rating. (2) Market risk - with a beta of 1.542, the stock is highly sensitive to market downturns. (3) Competitive risk - new entrants in diagnostics could pressure margins. (4) Macro risk - a recession could reduce pet spending, impacting revenue growth. The most severe risk is a growth deceleration below 8%, which could push the stock to the analyst low target of $470.
The 12-month forecast is a base case target of $698.92 (analyst average) with a 50% probability, a bull case of $805 with a 30% probability, and a bear case of $470 with a 20% probability. The most likely scenario is that the stock trades around $700, assuming revenue growth of 10-14%. The key assumption is that growth continues at current levels; if it accelerates, the stock could reach the high target, but if it decelerates, it could fall to the low target.
IDXX is overvalued relative to the industry average PE of 25x, trading at 51.4x trailing and 33.3x forward. The PEG ratio of 2.3 also suggests overvaluation. However, the premium is justified by its market leadership, high margins (61.8% gross), and strong growth. The market is pricing in significant future growth, which is a risk if growth disappoints. Relative to its own history, the stock is below its 52-week high of $769.98, but still above the low of $518.55, indicating it is not at a bargain level.
IDXX is a good buy for investors with a long-term horizon who believe in the growth of pet healthcare. The stock offers 25.5% upside to the average analyst target of $698.92, and the company's revenue growth is accelerating at 14.3% YoY. However, the valuation is rich at 51.4x trailing PE, so there is limited margin of safety. It is a good buy if you are comfortable with volatility and have a 3-5 year time frame, but not for short-term traders or those seeking value.
IDXX is more suitable for long-term investment due to its growth stage and high volatility (beta 1.542). The company has strong fundamentals and a dominant market position, which supports a long-term holding period of at least 3-5 years. Short-term trading is risky given the stock's 12% decline over the past year and high sensitivity to market sentiment. The lack of dividends means income investors should look elsewhere, but for growth investors, the long-term potential is significant.